Literature DB >> 18288180

Triggers, targets and treatments for thrombosis.

Nigel Mackman1.   

Abstract

Thrombosis--localized clotting of the blood--can occur in the arterial or the venous circulation and has a major medical impact. Acute arterial thrombosis is the proximal cause of most cases of myocardial infarction (heart attack) and of about 80% of strokes, collectively the most common cause of death in the developed world. Venous thromboembolism is the third leading cause of cardiovascular-associated death. The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood. Understanding these processes is crucial for developing safer and more effective antithrombotic drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288180      PMCID: PMC2848509          DOI: 10.1038/nature06797

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  56 in total

Review 1.  Direct thrombin inhibitors in acute coronary syndromes: present and future.

Authors:  Jeffrey I Weitz; Harry R Buller
Journal:  Circulation       Date:  2002-02-26       Impact factor: 29.690

2.  Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.

Authors:  Daniel J Quinlan; Andrew McQuillan; John W Eikelboom
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

Review 3.  The birth of the platelet.

Authors:  J Hartwig; J Italiano
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

4.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

5.  A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.

Authors:  Mohan N Babapulle; Lawrence Joseph; Patrick Bélisle; James M Brophy; Mark J Eisenberg
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

Review 6.  Role of tissue factor in hemostasis, thrombosis, and vascular development.

Authors:  Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-29       Impact factor: 8.311

Review 7.  Fondaparinux, the first selective factor Xa inhibitor.

Authors:  Alexander G G Turpie; Bengt I Eriksson; Michael R Lassen; Kenneth A Bauer
Journal:  Curr Opin Hematol       Date:  2003-09       Impact factor: 3.284

Review 8.  Haemophilias A and B.

Authors:  Paula H B Bolton-Maggs; K John Pasi
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

9.  Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice.

Authors:  L A Snyder; K A Rudnick; R Tawadros; A Volk; S H Tam; G M Anderson; P J Bugelski; J Yang
Journal:  J Thromb Haemost       Date:  2007-11-14       Impact factor: 5.824

10.  RNA aptamers as reversible antagonists of coagulation factor IXa.

Authors:  Christopher P Rusconi; Elizabeth Scardino; Juliana Layzer; George A Pitoc; Thomas L Ortel; Dougald Monroe; Bruce A Sullenger
Journal:  Nature       Date:  2002-09-05       Impact factor: 49.962

View more
  257 in total

Review 1.  Tissue factor and thrombosis: The clot starts here.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

Review 2.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 3.  P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Authors:  Christian Gachet
Journal:  Purinergic Signal       Date:  2012-04-11       Impact factor: 3.765

4.  Modeling hemodynamics in an unoccluded and partially occluded inferior vena cava under rest and exercise conditions.

Authors:  Zhuyin Ren; Stephen L Wang; Michael A Singer
Journal:  Med Biol Eng Comput       Date:  2012-02-22       Impact factor: 2.602

5.  Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice.

Authors:  M V Joglekar; Jerry Ware; Jin Xu; Malinda E C Fitzgerald; Theodore Kent Gartner
Journal:  Platelets       Date:  2012-06-21       Impact factor: 3.862

6.  Overexpression of microRNA-145 protects against rat myocardial infarction through targeting PDCD4.

Authors:  Hao Xu; Heng Cao; Guoqing Zhu; Shaowen Liu; Hongli Li
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 7.  Emerging paradigms in arterial thrombosis.

Authors:  James W Wisler; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

8.  Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Authors:  Harry R Büller; Claudette Bethune; Sanjay Bhanot; David Gailani; Brett P Monia; Gary E Raskob; Annelise Segers; Peter Verhamme; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2014-12-07       Impact factor: 91.245

9.  Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.

Authors:  Frauke Swieringa; Marijke J E Kuijpers; Moniek M E Lamers; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

10.  Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.

Authors:  Jun Deng; Heng Mei; Wei Shi; Zhi-Qing Pang; Bo Zhang; Tao Guo; Hua-Fang Wang; Xin-Guo Jiang; Yu Hu
Journal:  Curr Med Sci       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.